← Back to Screener
Lyell Immunopharma, Inc. Common Stock (LYEL)
Price$24.01
Favorite Metrics
Price vs S&P 500 (26W)36.68%
Price vs S&P 500 (4W)16.08%
Market Capitalization$559.60M
All Metrics
Book Value / Share (Quarterly)$11.68
P/TBV (Annual)0.51x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-92.48%
Cash Flow / Share (Quarterly)$-9.03
Price vs S&P 500 (YTD)-26.13%
Net Profit Margin (TTM)-762355.56%
EPS (TTM)$-15.41
10-Day Avg Trading Volume0.10M
EPS Excl Extra (TTM)$-15.41
Revenue Growth (5Y)-65.86%
EPS (Annual)$-16.06
ROI (Annual)-110.57%
Net Profit Margin (5Y Avg)-301538.54%
Cash / Share (Quarterly)$11.63
Revenue Growth QoQ (YoY)-45.45%
ROA (Last FY)-80.71%
Revenue Growth TTM (YoY)-40.98%
EBITD / Share (TTM)$-16.16
ROE (5Y Avg)-56.98%
Operating Margin (TTM)-745394.44%
Cash Flow / Share (Annual)$-9.03
P/B Ratio2.25x
P/B Ratio (Quarterly)2.63x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)13872.88x
ROA (TTM)-70.22%
EPS Incl Extra (Annual)$-16.06
Current Ratio (Annual)5.28x
Quick Ratio (Quarterly)5.00x
3-Month Avg Trading Volume0.11M
52-Week Price Return173.46%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.77
P/S Ratio (Annual)15544.57x
Asset Turnover (Annual)0.00x
52-Week High$45.00
Operating Margin (5Y Avg)-312062.62%
EPS Excl Extra (Annual)$-16.06
CapEx CAGR (5Y)-4.00%
26-Week Price Return45.43%
Quick Ratio (Annual)5.00x
13-Week Price Return2.34%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.28x
Enterprise Value$499.424
Revenue / Share Growth (5Y)-42.00%
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-762355.56%
Cash / Share (Annual)$11.63
3-Month Return Std Dev72.74%
Net Income / Employee (TTM)$-2
ROE (Last FY)-110.57%
EPS Basic Excl Extra (Annual)$-16.06
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-15.41
ROI (TTM)-90.52%
P/S Ratio (TTM)15544.57x
Pretax Margin (5Y Avg)-301538.54%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.34
Price vs S&P 500 (52W)138.37%
Year-to-Date Return-21.99%
5-Day Price Return-3.19%
EPS Normalized (Annual)$-16.06
ROA (5Y Avg)-44.72%
Net Profit Margin (Annual)-762355.56%
Month-to-Date Return19.69%
Cash Flow / Share (TTM)$-0.67
EBITD / Share (Annual)$-16.15
Operating Margin (Annual)-748344.44%
ROI (5Y Avg)-56.98%
EPS Basic Excl Extra (TTM)$-15.41
P/TBV (Quarterly)0.61x
P/B Ratio (Annual)2.63x
Pretax Margin (TTM)-762355.56%
Book Value / Share (Annual)$11.68
Price vs S&P 500 (13W)-0.52%
Beta0.11x
P/FCF (Annual)23.89x
Revenue / Share (TTM)$0.00
ROE (TTM)-90.52%
52-Week Low$7.65
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.89
3.89
3.89
3.90
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
LYELLyell Immunopharma, Inc. Common Stock | 15544.57x | -40.98% | — | — | $24.01 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
Lyell Immunopharma is a clinical-stage cell therapy company developing T-cell therapies for solid tumors through proprietary ex vivo genetic and epigenetic reprogramming technology. The company's pipeline includes three lead candidates: LYL797, LYL119, and LYL845.